NEWS DETAIL

  • Source : Press Release
  • Date : 2021-06-01
  • Event type : Marketed
  • Companies : Mabtech AB

More Path Kits!

Our Path universe is expanding - this time into a whole new dimension! Our CMV peptide pool has already been around for a while, binding both human HLA I and HLA II. But since then, we've confirmed which setup these peptides work best in to identify immune responses against CMV.

Venture into your very own CMV research with this validated combo, now available in our new ELISpot PathPRO: Human IFN-γ (CMV) and FluoroSpot Path: Human IFN-γ/IL-2 (CMV) kits.